Rapid and sustained decline in CXCL-10 (IP-10) annotates clinical outcomes following TNFα-antagonist therapy in hospitalized patients with severe and critical COVID-19 respiratory failure

Hachem, Hilal; Godara, Amandeep; Schroeder, Courtney; Fein, Daniel; Mann, Hashim; Lawlor, Christian; Marshall, Jill; Klein, Andreas K.; Poutsiaka, Deborah; Breeze, Janis L.; Joshi, Raghav; Mathew, Paul

doi:10.1017/cts.2021.805

Cited by 29 publications

(21 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…severe and critical COVID-19(71). Additionally, a prospective multicenter cohort of patients with IBD Treated by IFX or Vedolizumab during the COVID-19 pandemic was registered in the US (NCT04344249).…”

mentioning

confidence: 99%

Targeting TNF-α for COVID-19: Recent Advanced and Controversies

Guo

et al. 2022

Front. Public Health

View full text Add to dashboard Cite

Recent advances in the pathophysiologic understanding of coronavirus disease 2019 (COVID-19) suggests that cytokine release syndrome (CRS) has an association with the severity of disease, which is characterized by increased tumor necrosis factor α (TNF-α), interleukin (IL)-6, IL-2, IL-7, and IL-10. Hence, managing CRS has been recommended for rescuing severe COVID-19 patients. TNF-α, one of the pro-inflammatory cytokines commonly upregulated in acute lung injury, triggers CRS and facilitates SARS-CoV-2 interaction with angiotensin-converting enzyme 2 (ACE2). TNF-α inhibitors, therefore, may serve as an effective therapeutic strategy for attenuating disease progression in severe SARS-CoV-2 infection. Below, we review the possibilities and challenges of targeting the TNF-α pathway in COVID-19 treatment.

show abstract

mentioning

confidence: 99%

Targeting TNF-α for COVID-19: Recent Advanced and Controversies

Guo

et al. 2022

Front. Public Health

View full text Add to dashboard Cite

show abstract

“…Infliximab is a TNF-α inhibitor that has displayed efficacy and safety in restricting broad spectrum inflammation, and particularly in elderly populations who are most clinically vulnerable to COVID-19. In a small-scale clinical study, infliximab was found to abrogate pathological inflammatory signaling to facilitate clinical recovery in patients with severe or critical COVID-19 (76). More convincing evidence should be yielded by the WHO's Solidarity clinical trial in the future.…”

Section: Drugs That Regulate the Immune Systemmentioning

confidence: 97%

Drug discovery to treat COVID-19 two years after its outbreak

Gao

Sun

2021

DD&T

View full text Add to dashboard Cite

vaccine, drug, pandemic Coronavirus disease 2019 (COVID-19) has had a significant impact on human health and economic development over the past two years. Therapeutics in combination with vaccines are critical measures to fight the pandemic. The three areas of drug development are blocking the entry of SARS-CoV-2 into cells, suppressing viral replication inside cells, and regulating the immune system, and important advances have recently been made in those areas. Increasing numbers of neutralizing antibodies and small molecules that show promise have been fully approved or authorized for emergency use, resulting in decreased mortality of patients with COVID-19. The use of therapeutics will have a great impact on formulating and revising public policies to control the pandemic. The pace of lifting of restrictions and economic recovery worldwide will also accelerate in the future. Here, the drugs or agents that have attracted considerable attention and that have led to remarkable progress in the fight against COVID-19 are reviewed

show abstract

“…Trials targeting other inflammatory mediators are underway, although, surprisingly, the most abundantly used anti-inflammatory monoclonal antibodies, which target TNF and have been used in over 10 million autoimmune disease patients to date, have not yet been definitively evaluated for COVID-19 ( 71 – 74 ). IP-10 and MCP-1 may also be good candidate targets since their levels track with COVID-19 disease severity ( 75 ) and are associated with respiratory failure ( 76 ).…”

Section: The Covid-19 Therapeutic Landscapementioning

confidence: 99%

COVID-19 therapeutics: Challenges and directions for the future

Robinson

Liew

Tanner

et al. 2022

Proc. Natl. Acad. Sci. U.S.A.

127

View full text Add to dashboard Cite

The emergence of SARS-CoV-2 triggering the COVID-19 pandemic ranks as arguably the greatest medical emergency of the last century. COVID-19 has highlighted health disparities both within and between countries and will leave a lasting impact on global society. Nonetheless, substantial investment in life sciences over recent decades has facilitated a rapid scientific response with innovations in viral characterization, testing, and sequencing. Perhaps most remarkably, this permitted the development of highly effective vaccines, which are being distributed globally at unprecedented speed. In contrast, drug treatments for the established disease have delivered limited benefits so far. Innovative and rapid approaches in the design and execution of large-scale clinical trials and repurposing of existing drugs have saved many lives; however, many more remain at risk. In this review we describe challenges and unmet needs, discuss existing therapeutics, and address future opportunities. Consideration is given to factors that have hindered drug development in order to support planning for the next pandemic challenge and to allow rapid and cost-effective development of new therapeutics with equitable delivery.

show abstract

Rapid and sustained decline in CXCL-10 (IP-10) annotates clinical outcomes following TNFα-antagonist therapy in hospitalized patients with severe and critical COVID-19 respiratory failure

Abstract: Rapid and sustained decline in CXCL-10 (IP-10) annotates clinical outcomes following TNFα-antagonist therapy in hospitalized patients with severe and critical COVID-19 respiratory failure.

Cited by 29 publications

References 52 publications

Targeting TNF-α for COVID-19: Recent Advanced and Controversies

Targeting TNF-α for COVID-19: Recent Advanced and Controversies

Drug discovery to treat COVID-19 two years after its outbreak

COVID-19 therapeutics: Challenges and directions for the future

Contact Info

Product

Resources

About